Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Global research landscape of C3 glomerulopathy: A bibliometric analysis.

Created on 14 Aug 2026

Authors

Savas Ozturk

Published in

Clinical nephrology. Aug 14, 2026. Epub Aug 14, 2026.

Abstract

C3 glomerulopathy (C3G) is a rare, complement-mediated kidney disease with significant diagnostic and therapeutic challenges. Despite a growing number of publications, no study has comprehensively mapped the global research landscape. This bibliometric analysis aimed to evaluate publication trends, influential contributors, thematic evolution, and collaboration networks in C3G research from 1980 to 2025.
A systematic bibliometric analysis was conducted using PubMed-indexed publications from 1980 - 2025 retrieved with predefined Boolean queries. Eligible articles included original research and reviews addressing the pathophysiology, diagnosis, and management of C3G. Bibliometric parameters were analyzed using the Bibliometrix package in R (v4.3) and VOSviewer (v1.6.20). Citation data were verified via Google Scholar.
A total of 967 publications across 273 journals were identified. Research output increased exponentially after 2013, coinciding with the C3G Consensus Report and the rise of complement-targeted therapies. Pediatric Nephrology, Kidney International, and JASN were the leading publication venues. The United States, United Kingdom, and Italy were the most productive countries, with emerging contributions from China, India, and Türkiye. S. Sethi was the most prolific author (24 papers). Keyword co-occurrence and citation network analyses demonstrated a thematic shift from morphologic classification ("dense deposit disease") toward molecular and therapeutic paradigms ("complement inhibition," "iptacopan," "pegcetacoplan"). Collaboration networks remained modest and regionally clustered.
Global research on C3G has evolved from descriptive pathology toward precision complement therapeutics. However, significant geographical disparities persist, emphasizing the need for stronger international collaboration and equitable access to emerging complement inhibitors.

PMID:
42596752
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement